CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ChemoTech is developing a Dynamic-ElectroEnhanced Pain Control system to treat pain in cancer patients with secondary bone cancer. This innovative approach combines electric pulses with a low concentration of medication to reduce tumor size and alleviate nerve pressure.
This Phase 1 project will enable Scandinavian ChemoTech AB (ChemoTech) to develop a business plan for Dynamic-ElectroEnhanced Pain Control (D-EEPC).
This will include clinical and market feasibility, with a strong business development and commercialisation strategy.
Approximately 25% of all cancer patients are affected by secondary bone cancer; which is difficult to find and treat. 20-30% of these patients do not respond to current systemic therapies and pain control with narcotic analgesics, ra…
SCANDINAVIAN CHEMOTECH AB
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
